Navigation Links
Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors

SEATTLE, Jan. 31 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of Daniel H. Petree and George R. Painter, Ph.D. to the Company's board of directors.

Mr. Petree is a founder and member of P2 Partners, LLC, a boutique investment bank specializing in life science companies. Prior to forming P2 Partners, Mr. Petree held various executive management positions in the life sciences industry, including President and Chief Operating Officer of Axys Pharmaceuticals and Vice President of Business Development at TSI Corporation. He also served as Vice President in the Health Care Group at the investment bank Montgomery Securities. Mr. Petree currently serves as Director for Cypress BioSciences.

Dr. Painter is president and chief executive officer of Chimerix, a biotechnology company developing orally available antiviral therapeutics. Prior to that, he served as Executive Vice President, Research and Development, at Triangle Pharmaceuticals where he was a member of the founding management team. Dr. Painter has also held positions at Burroughs Wellcome Co., and Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over forty-five patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. Dr. Painter earned a B.S. in chemistry, an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry from Emory University.

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate, KP-1461 for the treatment of human immunodeficiency virus (HIV), is currently being evaluated in a Phase 2 trial. In addition to KP-1461, the Company has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

Tel : (206) 769-9219

SOURCE Koronis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Access Pharmaceuticals Announces $2.7 Million New Equity
4. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
5. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
6. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
7. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
9. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
10. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
(Date:6/27/2016)... Lemonade Stand Foundation (ALSF), a leading national childhood cancer ... bioinformatics lab, using ,big data, to advance the pace ... Liz Scott , co-executive director of ALSF and Alex,s ... Washington, D.C. , hosted by Vice President ... pediatric cancer research and awareness. The ...
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):